Want to see CRDF full AI Analyst Report?
CRDF Stock Chart & Stats
$1.02
$0.02(2.30%)
At close: 4:00 PM EDT
$1.02
$0.02(2.30%)
Day’s Range― - ―
52-Week Range$0.76 - $3.31
Previous CloseN/A
Volume462.43K
Average Volume (3M)751.44K
Market Cap
$84.80M
Enterprise Value$54.85
Total Cash (Recent Filing)$34.52M
Total Debt (Recent Filing)$457.00K
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Oct 29, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding77,795,250
10 Day Avg. Volume655,800
30 Day Avg. Volume751,436
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.14
Price to Sales (P/S)316.73
P/FCF Ratio-4.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside488.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.6
Revenue Forecast (FY)$282.13K
Bulls Say, Bears Say
Bulls Say
Low LeverageExtremely low leverage limits debt-service pressure and preserves financial flexibility for a development-stage biotech. Cardiff Oncology is less exposed to refinancing stress than a highly indebted peer, although future funding needs could still affect shareholder dilution.
Clinical Development PotentialPromising interim Phase 2 data and a stated registrational path provide evidence that onvansertib could advance toward a commercially meaningful oncology opportunity. Continued clinical progress would strengthen the pipeline’s strategic value and improve future partnering or financing prospects.
Recent Liquidity RaiseThe completed $10 million financing provides near-term liquidity to sustain operations and advance the oncology pipeline without relying solely on an immediate clinical or licensing outcome. Insider participation also indicates involvement from company officers and directors, though the structure carries dilution implications.
Bears Say
Pre-commercial Revenue ProfileCardiff Oncology remains firmly pre-commercial, generating minimal and declining revenue while absorbing very large operating losses. This model leaves financial performance dependent on successful clinical and regulatory execution rather than established product demand, extending the period before sustainable earnings can emerge.
Persistent Cash BurnSustained negative operating and free cash flow means research and development spending is not currently funded by internally generated cash. Continued cash burn creates recurring dependence on equity, debt, or strategic financing, which can constrain flexibility and increase dilution risk if losses persist.
License Litigation UncertaintyA dispute over termination of the onvansertib license creates uncertainty around intellectual-property rights and the continuity of Cardiff Oncology’s central development program. Prolonged litigation or an unfavorable outcome could delay clinical advancement, weaken negotiating leverage, or impair the pipeline’s future value.
Cardiff Oncology News
CRDF FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was $0.76 and its highest was $3.31 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Cardiff Oncology, Inc.’s market cap is $84.80M.
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is Oct 29, 2026 which is in 51 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.02.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Cardiff Oncology, Inc. have?
Cardiff Oncology, Inc. has 77,795,250 shares outstanding.
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went down -5.714%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Currently, no hedge funds are holding shares in CRDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiff Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (488.24% Upside)
$6.00 (488.24% Upside)
Blogger Sentiment
Bullish
CRDF Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 37.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-50.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
CRDF Stock 12 Month Forecast
Average Price Target
$6.00
▲(488.24% Upside)
Technical Analysis
Oncolytics Biotech
―
―
Avalo Therapeutics
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Ownership Overview
2.89% Insiders
6.97% Mutual Funds
9.33% Other Institutional Investors
76.89% Public Companies and
Individual Investors